ADOC — Adocia SA Share News
0.000.00%
Last trade - 00:00- €82.83m
- €74.48m
- €1.48m
Brief: Adocia Reports Financial Results Q1 2023
Brief: Adocia Is In Discussions With Its Lenders To Restructure Its Debt
Brief: Adocia Announces Successful Phase 1 Study For Biochaperone Lispro With Partner Tonghua Dongbao
Brief: Adocia Strengthens Cash Position With 6 Million Euros Through Convertible Bonds Issuance
Brief: Adocia Q3 Revenue Up At EUR 2.4 Million
Brief: Adocia's M1Pram Leads To Weight Loss For Obese People With Type 1 Diabetes
Brief: Adocia H1 Net Result Turns To Profit Of EUR 4.3 Mln
Brief: Adocia: First Cell Therapy Preclinical Proof of Concept of AdoShell Islets
Brief: Adocia Q2 Revenue Up At EUR 6.8 Mln
Brief: Adocia Says M1pram Phase 2 Trial Meets Primary Objective By Reducing Weight In Overweight People With Type 1 Diabetes
Brief: Adocia Q1 Revenue Up At EUR 0.6 Mln
Brief: Adocia: First Patient Dosed In Biochaperone Lispro Phase 3 Programme
Brief: Adocia FY Operating Loss Narrows To EUR 19.4 Mln
Brief: Adocia Sells Building In Lyon For More Than EUR 20 Mln
Brief: Adocia Announces 2021 Fourth Quarter Financial Results
Brief: Adocia FY Revenue Up At 1.4 Million Euros
Brief: Adocia Files Patent For Technology To Enable Oral Drug Delivery Of Peptides
Brief: Adocia's Partner Tonghua Dongbao Receives Clearance To Start Biochaperone® Lispro Phase 3 Trial in China
Brief: Adocia End-June Operating Loss Narrows At 9.6 Million Euros